Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

scientific article

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/JVI.78.23.13232-13252.2004
P3181OpenCitations bibliographic resource ID1379316
P932PMC publication ID524984
P698PubMed publication ID15542675

P50authorBette KorberQ30505218
Renate KunertQ51764661
Dennis R. BurtonQ56331320
Christos J PetropoulosQ84542015
P2093author name stringMeng Wang
James M Binley
Susan Zolla-Pazner
Michael B Zwick
Colombe Chappey
Terri Wrin
Hermann Katinger
Gabriela Stiegler
P2860cites workImmunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccinesQ24531479
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individualsQ24560010
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitroQ24563642
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Q24645530
Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Q27469855
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine designQ27634018
Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivityQ27640463
Antibody domain exchange is an immunological solution to carbohydrate cluster recognitionQ27641517
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52DQ27643126
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyQ27759364
Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE proteinQ28140278
Complete nucleotide sequence of the AIDS virus, HTLV-IIIQ28259080
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutininQ28264707
Antibody neutralization and escape by HIV-1Q29547345
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodiesQ29614531
Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombinationQ29616724
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibodyQ29618366
Rapid evolution of the neutralizing antibody response to HIV type 1 infectionQ29618603
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sitesQ29619017
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1Q29619512
Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction.Q30416612
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.Q30423779
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexesQ30706865
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Q31016954
Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.Q31016969
Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusionQ32127339
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesQ33603494
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progressionQ33604871
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Q33647300
Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulinsQ33783353
Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopesQ33783763
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.Q33786382
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypesQ33787329
Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African CitiesQ33795045
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infectionQ33825654
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Q33835295
Isolation and characterization of two divergent infectious molecular clones of HIV type 1 longitudinally obtained from a seropositive patient by a progressive amplification procedureQ38942024
The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phasesQ38976321
Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.Q39090313
An infectious DNA clone of HIV type 1 subtype C.Q39257045
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domainQ39313963
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.Q39358702
Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 IsolateQ39484956
Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIVQ39550518
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable regionQ39602963
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.Q39605077
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptorQ39686562
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.Q39868309
Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding siteQ39875133
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.Q39879382
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.Q40038304
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.Q40757568
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.Q40832863
Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory workerQ40883803
Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope proteinQ40937092
Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.Q40991774
Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.Q41065899
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120Q41078744
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.Q41151327
Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.Q41171978
A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.Q41419602
Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte ImmortalizationQ41478638
Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120Q41632477
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoproteinQ41645847
The antibody response in HIV-1 infection.Q41694946
Dissociation of gp120 from HIV-1 virions induced by soluble CD4.Q41714439
Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in NigeriaQ42692037
Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators.Q43610425
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.Q43872744
Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents.Q43951264
Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.Q44102674
Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.Q44160155
Determining neutralization serotypes of HIV type 1 by neural networksQ44391893
Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodiesQ45168377
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.Q45662866
Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodiesQ45670204
Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptorsQ45699140
Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.Q45736635
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infectionQ45744790
Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulinsQ45762836
Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolatesQ45763324
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assayQ45766845
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine EvQ45771982
International collaboration comparing neutralization and binding assays for monoclonal antibodies to simian immunodeficiency virusQ45786878
HIV-1 nomenclature proposal.Q48750867
HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. WHO Network for HIV Isolation and CharacterizationQ56921434
Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical TrialsQ58038926
Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5Q58038933
HIV Type 1 Variation in World Health Organization-Sponsored Vaccine Evaluation Sites: Genetic Screening, Sequence Analysis, and Preliminary Biological Characterization of Selected Viral StrainsQ58415406
Molecular Characterization of Five Neutralizing Anti-HIV Type 1 Antibodies: Identification of Nonconventional D Segments in the Human Monoclonal Antibodies 2G12 and 2F5Q61554599
Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strainsQ67967850
Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogenQ71848107
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120Q72067428
Interfering With Inflammation During Cell-Cell InteractionQ93606952
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine developmentQ33842152
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitroQ33853775
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Q33870236
Genetic analysis reveals epidemiologic patterns in the spread of human immunodeficiency virusQ33925746
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunityQ33961624
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Q33979107
Understanding the genetic diversity of HIV-1.Q34087006
Diversity considerations in HIV-1 vaccine selectionQ34136023
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.Q34145199
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical TriaQ34171212
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1Q34292765
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1Q34306804
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52DQ34323863
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South AfricaQ34332009
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cellsQ34338761
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.Q34341843
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.Q34342352
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kineticsQ34415921
Neutralizing antiviral antibody responsesQ34419527
Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.Q34445941
Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.Q34619876
Antibodies, viruses and vaccinesQ34810301
Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 PseudovirionsQ34977075
Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce FusionQ34977118
Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.Q35155451
HIV vaccines 1983-2003.Q35166836
Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibodyQ35170702
Antibody protection: passive immunization of neonates against oral AIDS virus challenge.Q35172885
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.Q35839973
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.Q35849408
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virusQ35849627
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.Q35853750
Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent iQ35853761
Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.Q35854300
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.Q35857331
Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and AfricaQ35860840
Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and CharacterizationQ35872254
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1Q35880498
Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptorQ35890867
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.Q35894716
A vaccine for HIV type 1: the antibody perspectiveQ36037760
Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.Q36366296
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodiesQ36620408
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.Q36623941
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.Q36628256
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.Q36633402
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodiesQ36634439
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.Q36634499
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralizationQ36635390
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodiesQ36638240
Defining critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and peptide array technologies.Q36673577
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibodyQ36687562
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulationQ36783052
Multivariate analysis of human immunodeficiency virus type 1 neutralization dataQ36808080
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.Q36954472
A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and TobagoQ37250834
Evidence for limited within-person evolution of the V3 domain of the HIV-1 envelope in the amsterdam population.Q38507860
Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and CQ38889279
Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolatesQ38900264
P433issue23
P407language of work or nameEnglishQ1860
P921main subjectantibodyQ79460
monoclonal antibodyQ422248
virusQ808
virologyQ7215
P304page(s)13232-52
P577publication date2004-12-01
P1433published inJournal of VirologyQ1251128
P1476titleComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
P478volume78

Reverse relations

cites work (P2860)
Q4224716510E8-like neutralizing antibodies against HIV-1 induced using a precisely designed conformational peptide as a vaccine prime
Q335474514E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms
Q364839564E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response
Q27655865A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies
Q34204188A General Approach for Receptor and Antibody-Targeted Detection of Native Proteins Utilizing Split-Luciferase Reassembly
Q35566508A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens
Q27675032A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Q26851165A brief history of the global effort to develop a preventive HIV vaccine
Q45409784A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Q36149102A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.
Q34741807A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection
Q39733091A covalent HIV vaccine: is there hope for the future?
Q28743092A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein
Q33954392A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus
Q57920783A dynamic three-step mechanism drives the HIV-1 pre-fusion reaction
Q34396912A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1
Q27485578A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies
Q36748055A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120
Q31132248A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
Q34172295A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice
Q27649541A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120
Q33786140A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy
Q33653774A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays
Q37102810A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide
Q34463861A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop
Q36827883A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization
Q45888461A vaccine that delivers rather than induces antibodies
Q37694976Accessing the human repertoire for broadly neutralizing HIV antibodies
Q35077704Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic
Q64253147Adenosine deaminase-1 delineates human follicular helper T cell function and is altered with HIV
Q36099376Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection
Q27489000Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
Q36600380Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
Q38342167Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop
Q33272711An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
Q35109028An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus
Q33820645An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120
Q40359188Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates
Q33526340Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
Q37033400Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
Q40147993Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis
Q33377024Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site
Q28752503Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
Q35641369Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency
Q27489392Antibodies against viruses: passive and active immunization
Q36141515Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens
Q37127735Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine
Q36759899Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG
Q30843874Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
Q38293417Antibody recognition of HIV and dengue glycoproteins
Q35024202Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo
Q26991572Antibody responses to envelope glycoproteins in HIV-1 infection
Q90677040Antibody responses to the HIV-1 envelope high mannose patch
Q37333772Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors
Q24536059Antibody vs. HIV in a clash of evolutionary titans
Q30408097Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies
Q42738983Antibody-based HIV-1 vaccines: recent developments and future directions
Q35658856Antibody-based protection against HIV infection by vectored immunoprophylaxis
Q39108751Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development
Q56837789Anticardiolipin Antibodies in HIV Infection Are Independently Associated with Antibodies to the Membrane Proximal External Region of gp41 and with Cell‐Associated HIV DNA and Immune Activation
Q38884485Anticipating policy considerations for a future HIV vaccine: a preliminary study
Q35785338Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy
Q36403587Antigenic conservation and immunogenicity of the HIV coreceptor binding site
Q37547245Antigenic properties of the HIV envelope on virions in solution
Q27320687Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells
Q35933555Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins
Q35580892Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate
Q30375834Appreciating HIV type 1 diversity: subtype differences in Env.
Q34774808Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines
Q33667654Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions
Q34008699Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.
Q36248882Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes.
Q40145762Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
Q27680125Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10
Q34008741B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses
Q34597300Back to the future: covalent epitope-based HIV vaccine development
Q35689608Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions
Q35192937Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site
Q39896978Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins
Q39240591Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5.
Q33780524Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines
Q35973601Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells
Q35164477Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals
Q37438127Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies
Q33614495Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
Q36174694Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization
Q36697992Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
Q29615361Broad neutralization coverage of HIV by multiple highly potent antibodies
Q33417195Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope
Q37410792Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region
Q35785010Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor
Q36571900Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo
Q38707583Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response
Q38065391Broadly neutralizing antibodies against HIV-1: templates for a vaccine
Q46683819Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Q33444658Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
Q35012462Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
Q22242739CCR5 monoclonal antibodies for HIV-1 therapy
Q39084604CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection
Q36469664CD4 binding determinant mimicry for HIV vaccine design
Q37998496Candidate antibody-based therapeutics against HIV-1.
Q37426039Carbohydrate vaccines: developing sweet solutions to sticky situations?
Q24655912Catalytic antibodies to HIV: physiological role and potential clinical utility
Q34229664Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies
Q44176443Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection
Q33798076Characteristics of the earliest cross-neutralizing antibody response to HIV-1.
Q38947061Characterization of a SHIV162P3 variant evolved in an infected rhesus macaque with persistent plasma viremia.
Q40834595Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques
Q37072702Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.
Q34988326Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses
Q34594591Cholesterol-dependent membrane fusion induced by the gp41 membrane-proximal external region-transmembrane domain connection suggests a mechanism for broad HIV-1 neutralization.
Q35164416Co-expression of foreign proteins tethered to HIV-1 envelope glycoprotein on the cell surface by introducing an intervening second membrane-spanning domain
Q34807480Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers
Q30994182Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes
Q33984309Comparing antigenicity and immunogenicity of engineered gp120.
Q33867353Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease
Q34663118Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques
Q54209545Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China.
Q44106801Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China
Q37456637Complement and antibodies: a dangerous liaison in HIV infection?
Q38673539Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
Q34934438Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18
Q37153097Conservation, Compensation, and Evolution of N-Linked Glycans in the HIV-1 Group M Subtypes and Circulating Recombinant Forms
Q27663325Conserved structural elements in the V3 crown of HIV-1 gp120
Q28554907Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene
Q30369026Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
Q34543052Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.
Q37329415Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
Q37671423Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities
Q33274285Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies
Q36105782Cross-reactive broadly neutralizing antibodies: timing is everything
Q36747750Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens
Q37445549Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
Q37256644Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1
Q27661588Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction
Q27657585Crystal structure of a 3B3 variantâ A broadly neutralizing HIV-1 scFv antibody
Q42031529Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity
Q27657377Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications
Q36415785Current advances and challenges in HIV-1 vaccines
Q33840789Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds
Q57226425Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
Q27684578Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization
Q36057328Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet
Q34094476Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies
Q38739398Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies
Q40430180Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration
Q35060140Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system
Q41933100Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells
Q33827798Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production
Q91528949Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations
Q33780961Dimeric 2G12 as a potent protection against HIV-1.
Q42850455Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity
Q47765958Directed Evolution of Glycopeptides Using mRNA Display
Q41879689Directed evolution of 2G12-targeted nonamannose glycoclusters by SELMA.
Q35092308Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies
Q35124652Directed evolution of multivalent glycopeptides tightly recognized by HIV antibody 2G12.
Q35857221Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
Q52689038Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion.
Q38962226Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope
Q29617562Distribution and three-dimensional structure of AIDS virus envelope spikes
Q64079873Diverse Large HIV-1 Non-subtype B Clusters Are Spreading Among Men Who Have Sex With Men in Spain
Q37644030Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
Q37336404Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfection
Q33504556Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation
Q90281664Effect of diversity in gp41 membrane proximal external region of primary HIV-1 Indian subtype C sequences on interaction with broadly neutralizing antibodies 4E10 and 10E8
Q33571825Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein
Q35101333Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
Q33431668Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library
Q27664711Elicitation of structure-specific antibodies by epitope scaffolds
Q38989627Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines
Q36956100Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1
Q46108373Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes
Q33313394Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.
Q80146188Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes
Q37344582Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo
Q35076987Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected
Q33888559Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects
Q45406304Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
Q33883887Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
Q34819651Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic
Q34648079Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1
Q35785164Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations
Q36388754Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
Q33518005Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies
Q33676640Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model
Q37183108Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
Q35033324Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.
Q36802333Exploiting the defensive sugars of HIV-1 for drug and vaccine design
Q45351263Expression and immunological characterization of cardamom mosaic virus coat protein displaying HIV gp41 epitopes
Q34175370Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity
Q79316750Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1
Q47547492FUNCTIONAL OPTIMIZATION OF BROADLY NEUTRALIZING HIV-1 ANTIBODY 10E8 BY PROMOTING MEMBRANE INTERACTIONS.
Q37033294Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
Q34717733Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1
Q46545827Fc receptor but not complement binding is important in antibody protection against HIV.
Q36081789Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
Q35491705Feline immunodeficiency virus (FIV) neutralization: a review
Q80150785Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
Q36192967Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection.
Q36814871Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41
Q33911809Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses
Q37033269Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
Q40289677Functional Contacts between MPER and the Anti-HIV-1 Broadly Neutralizing Antibody 4E10 Extend into the Core of the Membrane
Q35168642Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
Q40127843Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion
Q33749206Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission
Q36171855Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates
Q33558279Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1
Q35914553Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees
Q44666638Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs).
Q35140032Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa
Q34800408Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China
Q35843775Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example
Q43611862Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies
Q33719511Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies
Q34392963Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies
Q39824069Glycosylation site-specific analysis of clade C HIV-1 envelope proteins
Q60300930Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant
Q36249933HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions
Q27026662HIV broadly neutralizing antibody targets
Q39806672HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase
Q37851950HIV vaccines: progress to date.
Q33887674HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.
Q33552488HIV-1 and influenza antibodies: seeing antigens in new ways
Q34990575HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans
Q37360774HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.
Q34399542HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile
Q44942815HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120.
Q35640998HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies
Q33869882HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies
Q37405645HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses
Q27000480HIV-1 neutralizing antibodies: understanding nature's pathways
Q34485336HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies
Q41918917HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites
Q34243456HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form
Q41823383HIV-2 neutralization by intact V3-specific Fab fragments
Q39539756HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line
Q39617158Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence
Q33920519High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz
Q38732360High temperature SELMA: evolution of DNA-supported oligomannose clusters which are tightly recognized by HIV bnAb 2G12.
Q37179996Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India
Q27676155Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure
Q29307502Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope
Q36757139Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice
Q28602877Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
Q30404393Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review
Q37247974Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
Q29619015Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
Q37051645Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma
Q37388409Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors
Q36171536Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.
Q39108796Identification and specificity of broadly neutralizing antibodies against HIV
Q35592911Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual
Q34428738Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.
Q40128614Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120.
Q45419055Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection
Q40415206Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization
Q34229329Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa
Q36736610Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody
Q37250899Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state
Q41925820Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.
Q37842335Immunotherapeutic restoration in HIV-infected individuals
Q37729781Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
Q34593647Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies
Q36949880Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response
Q36804634Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination
Q39783358Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection
Q41936036In vitro inhibition of HIV-1 replication in autologous CD4(+) T cells indicates viral containment by multifactorial mechanisms.
Q34974016In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge
Q35947769In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
Q33725718In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1
Q36496923Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.
Q33392865Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing
Q44138330Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
Q52896722Induction of antibodies binding to the membrane proximal external region of gp36 of HIV-2.
Q34517381Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
Q34983331Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.
Q37789226Inhibition of HIV-1 entry: multiple keys to close the door
Q33897480Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region
Q28469023Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B
Q27658138Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity
Q39265131Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections
Q39843176Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype
Q36103090Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens
Q37245921Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes
Q46078929Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.
Q34630446Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
Q46310805Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies
Q34206171Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.
Q33374701Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120
Q34648499Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
Q40113932Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.
Q34784621MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide
Q34681455MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.
Q35857254Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies
Q34157802Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine
Q36107520Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin
Q33910507Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120
Q35260162Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies
Q37410770Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment
Q37208595Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.
Q46441250Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes.
Q42576275Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies
Q36127736MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency
Q42241364Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling
Q35029737Modulation of HIV Binding to Epithelial Cells and HIV Transfer from Immature Dendritic Cells to CD4 T Lymphocytes by Human Lactoferrin and its Major Exposed LF-33 Peptide
Q36981930Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy
Q34071790Molecular evolution of HIV-1 CRF01_AE Env in Thai patients
Q33372270Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.
Q35635418Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites
Q36404752Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120.
Q35904501Monoclonal antibody-based candidate therapeutics against HIV type 1.
Q84974132Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1
Q47218587Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.
Q34712503Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA
Q36475897Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins
Q41844960Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus
Q36099045N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization
Q36565090N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus
Q35864051N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03
Q34434854Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
Q89548775Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization
Q34304203Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.
Q45421316Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity
Q34301874Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant
Q38864042Neutralization of HIV subtypes A and D by breast milk IgG from women with HIV infection in Uganda.
Q40909337Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection
Q28483205Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India
Q39206567Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India
Q45460445Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability.
Q33382060Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection
Q36837324Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark
Q37252676Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge
Q34550046Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success
Q39934862Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity
Q47566038Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells
Q35208657Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination
Q33887693Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?
Q37971867Neutralizing antibodies and control of HIV: moves and countermoves.
Q34055377Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production
Q81816292Neutralizing antibodies take a swipe at HIV in vivo
Q36603515Neutralizing antibodies to HIV-1 induced by immunization.
Q24655129Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors
Q34651668Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses
Q35826306Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane
Q35275117Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs
Q36414162Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.
Q21089590Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10
Q37417794Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens
Q33693391Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.
Q37099857Origin and biology of simian immunodeficiency virus in wild-living western gorillas
Q30358434Passive immunization against HIV/AIDS by antibody gene transfer.
Q38954558Peripheral Membrane Interactions Boost the Engagement by an Anti-HIV-1 Broadly Neutralizing Antibody
Q37034639Perspectives for a protective HIV-1 vaccine
Q37105366Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database
Q40239519Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model
Q37220020Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China.
Q30402036Phylogenetic structure in African HIV-1 subtype C revealed by selective sequential pruning
Q36694846Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates
Q38023086Plant made anti-HIV microbicides--a field of opportunity
Q24635002Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals
Q37094429Polyvalent AIDS vaccines
Q45417687Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Q34742533Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop
Q33895810Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.
Q35415717Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
Q35124761Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method
Q38343551Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates
Q33702217Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Q38206519Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).
Q56892297Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice
Q34551010Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate
Q40043685Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design
Q36384117Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors
Q36974754Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
Q51830138Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.
Q42215329Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.
Q38574172Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction
Q37584635Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.
Q33725673Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors
Q29619511Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
Q35603504Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
Q37119451Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination
Q51802993Recognition and blocking of HIV-1 gp41 pre-transmembrane sequence by monoclonal 4E10 antibody in a Raft-like membrane environment.
Q33911935Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines
Q40766118Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants.
Q36837815Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization
Q45365167Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence
Q34357068Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.
Q40204965Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
Q38632078Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function
Q28075274Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Q35635163Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection
Q39723388Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
Q38046828Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.
Q33898131Role of humoral immunity in host defense against HIV.
Q41019767Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults
Q36184440Saturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations
Q41933070Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
Q33262382Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning
Q34456367Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China
Q36634965Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes
Q36638489Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals
Q40311562Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma
Q34103170Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions
Q37084521Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses
Q40397998Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis
Q34415389Specificity of the autologous neutralizing antibody response
Q35065249Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic
Q30784057Statistical approaches to analyzing HIV-1 neutralizing antibody assay data
Q27658173Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens
Q57292375Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan
Q36281210Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
Q35122067Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1
Q27681352Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope
Q36856960Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors
Q27650903Structure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data set
Q27649247Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization
Q34987048Structure-based vaccine design in HIV: blind men and the elephant?
Q34353296Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody
Q35196671Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
Q34128200Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.
Q34499013Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity
Q36424523Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins
Q37704735Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection
Q35947805Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies
Q37143743Sustained release of proteins from a modified vaginal ring device.
Q37333743T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces
Q37246321Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies
Q37179763Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding
Q34146546The MHC class II cofactor HLA-DM interacts with Ig in B cells
Q33883936The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner
Q42013922The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.
Q36898696The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
Q36483346The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection
Q30367176The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Q52581587The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.
Q45362788The effect of human immunodeficiency virus type 1 (HIV-1) gp41 variability on antibody detection
Q85228912The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies
Q57460198The expanding array of HIV broadly neutralizing antibodies
Q40051843The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen
Q35140408The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population
Q28275986The good and evil of complement activation in HIV-1 infection
Q37099851The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions
Q40414065The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles
Q37667754The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.
Q36384607The membrane proximal external regions of gp41 from HIV-1 strains HXB2 and JRFL have different sensitivities to alanine mutation.
Q36497712The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
Q34017550The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.
Q35644971The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization
Q39822146The six-helix bundle of human immunodeficiency virus Env controls pore formation and enlargement and is initiated at residues proximal to the hairpin turn
Q42185150Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12.
Q33614365Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies
Q57697548Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques
Q37962848Toward automated oligosaccharide synthesis
Q37431843Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity
Q37348636Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.
Q33826682Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain
Q35943810UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C
Q34441935Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization
Q35857683Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.
Q92538999Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization
Q34203163Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection
Q34178341Very few substitutions in a germ line antibody are required to initiate significant domain exchange.
Q35948073Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.
Q30603475Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography
Q33772637Which Antibody Functions are Important for an HIV Vaccine?
Q24567758bNAber: database of broadly neutralizing HIV antibodies

Search more.